Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elise Landais is active.

Publication


Featured researches published by Elise Landais.


Immunity | 2013

Human Circulating PD-1+CXCR3−CXCR5+ Memory Tfh Cells Are Highly Functional and Correlate with Broadly Neutralizing HIV Antibody Responses

Michela Locci; Colin Havenar-Daughton; Elise Landais; Jennifer E. Wu; Mark A. Kroenke; Cecilia S. Lindestam Arlehamn; Laura F. Su; Rafael Cubas; Mark M. Davis; Alessandro Sette; Elias K. Haddad; Pascal Poignard; Shane Crotty

The vast majority of currently licensed human vaccines work on the basis of long-term protective antibody responses. It is now conceivable that an antibody-dependent HIV vaccine might be possible, given the discovery of HIV broadly neutralizing antibodies (bnAbs) in some HIV-infected individuals. However, these antibodies are difficult to develop and have characteristics indicative of a high degree of affinity maturation in germinal centers (GCs). CD4⁺ T follicular helper (Tfh) cells are specialized for B cell help and necessary for GCs. Therefore, the development of HIV bnAbs might depend on Tfh cells. Here, we identified in normal individuals a subpopulation of circulating memory PD-1⁺CXCR5⁺CD4⁺ T cells that are resting memory cells most related to bona fide GC Tfh cells by gene expression profile, cytokine profile, and functional properties. Importantly, the frequency of these cells correlated with the development of bnAbs against HIV in a large cohort of HIV⁺ individuals.


PLOS Pathogens | 2016

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.

Elise Landais; Xiayu Huang; Colin Havenar-Daughton; Ben Murrell; Matthew Price; Lalinda Wickramasinghe; Alejandra Ramos; Charoan B. Bian; Melissa Simek; Susan Allen; Etienne Karita; William Kilembe; Shabir Lakhi; Mubiana Inambao; Anatoli Kamali; Eduard J. Sanders; Omu Anzala; Vinodh Edward; Linda-Gail Bekker; Jianming Tang; Jill Gilmour; Sergei L. Kosakovsky-Pond; Pham Phung; Terri Wrin; Shane Crotty; Adam Godzik; Pascal Poignard

Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protective HIV vaccine. However, designing vaccines immunogens able to elicit bnAbs has proven unsuccessful to date. Understanding the correlates and immunological mechanisms leading to the development of bnAb responses during natural HIV infection is thus critical to the design of a protective vaccine. The IAVI Protocol C program investigates a large longitudinal cohort of primary HIV-1 infection in Eastern and South Africa. Development of neutralization was evaluated in 439 donors using a 6 cross-clade pseudo-virus panel predictive of neutralization breadth on larger panels. About 15% of individuals developed bnAb responses, essentially between year 2 and year 4 of infection. Statistical analyses revealed no influence of gender, age or geographical origin on the development of neutralization breadth. However, cross-clade neutralization strongly correlated with high viral load as well as with low CD4 T cell counts, subtype-C infection and HLA-A*03(-) genotype. A correlation with high overall plasma IgG levels and anti-Env IgG binding titers was also found. The latter appeared not associated with higher affinity, suggesting a greater diversity of the anti-Env responses in broad neutralizers. Broadly neutralizing activity targeting glycan-dependent epitopes, largely the N332-glycan epitope region, was detected in nearly half of the broad neutralizers while CD4bs and gp41-MPER bnAb responses were only detected in very few individuals. Together the findings suggest that both viral and host factors are critical for the development of bnAbs and that the HIV Env N332-glycan supersite may be a favorable target for vaccine design.


Proceedings of the National Academy of Sciences of the United States of America | 2016

CXCL13 is a plasma biomarker of germinal center activity

Colin Havenar-Daughton; Madelene Lindqvist; Antje Heit; Jennifer E. Wu; Samantha M. Reiss; Kayla Kendric; Simon Bélanger; Sudhir Pai Kasturi; Elise Landais; Rama Akondy; Helen M. McGuire; Marcella Bothwell; Parsia A. Vagefi; Eileen Scully; Georgia D. Tomaras; Mark M. Davis; Pascal Poignard; Rafi Ahmed; Bruce D. Walker; Bali Pulendran; M. Juliana McElrath; Daniel E. Kaufmann; Shane Crotty

Significance A major challenge for vaccine science is that there is no way to measure germinal center activity in humans. This challenge is particularly acute for human clinical trials of candidate vaccines (and most nonhuman primate studies of candidate vaccines), because germinal centers are the engines of Ab affinity maturation, and generation of highly affinity-matured Ab responses is the goal of all Ab-eliciting vaccines. Here, we report that we have identified the chemokine CXCL13 [chemokine (C-X-C motif) ligand 13] as a biomarker of germinal center activity. We show explicit relationships between plasma CXCL13 concentrations and germinal center frequencies in lymph nodes in a series of different conditions, including licensed and experimental vaccines, and in humans, nonhuman primates, and mice. Significantly higher levels of plasma CXCL13 [chemokine (C-X-C motif) ligand 13] were associated with the generation of broadly neutralizing antibodies (bnAbs) against HIV in a large longitudinal cohort of HIV-infected individuals. Germinal centers (GCs) perform the remarkable task of optimizing B-cell Ab responses. GCs are required for almost all B-cell receptor affinity maturation and will be a critical parameter to monitor if HIV bnAbs are to be induced by vaccination. However, lymphoid tissue is rarely available from immunized humans, making the monitoring of GC activity by direct assessment of GC B cells and germinal center CD4+ T follicular helper (GC Tfh) cells problematic. The CXCL13–CXCR5 [chemokine (C-X-C motif) receptor 5] chemokine axis plays a central role in organizing both B-cell follicles and GCs. Because GC Tfh cells can produce CXCL13, we explored the potential use of CXCL13 as a blood biomarker to indicate GC activity. In a series of studies, we found that plasma CXCL13 levels correlated with GC activity in draining lymph nodes of immunized mice, immunized macaques, and HIV-infected humans. Furthermore, plasma CXCL13 levels in immunized humans correlated with the magnitude of Ab responses and the frequency of ICOS+ (inducible T-cell costimulator) Tfh-like cells in blood. Together, these findings support the potential use of CXCL13 as a plasma biomarker of GC activity in human vaccine trials and other clinical settings.


Immunity | 2016

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Daniel T. MacLeod; Nancy M. Choi; Bryan Briney; Fernando Garces; Lorena S. Ver; Elise Landais; Ben Murrell; Terri Wrin; William Kilembe; Chi-Hui Liang; Alejandra Ramos; Chaoran B. Bian; Lalinda Wickramasinghe; Leopold Kong; Kemal Eren; Chung-Yi Wu; Chi-Huey Wong; Matthew Price; Jill Gilmour; Pat Fast; Anatoli Kamali; Eduard J. Sanders; Omu Anzala; Susan Allen; Eric Hunter; Etienne Karita; Shabir Lakhi; Mubiana Inambao; Vinodh Edward; Linda-Gail Bekker

The high-mannose patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no vaccination regimen has elicited bnAbs against this region. Here, we present the development of a bnAb lineage targeting the high-mannose patch in an HIV-1 subtype-C-infected donor from sub-Saharan Africa. The Abs first acquired autologous neutralization, then gradually matured to achieve breadth. One Ab neutralized >47% of HIV-1 strains with only ∼11% somatic hypermutation and no insertions or deletions. By sequencing autologous env, we determined key residues that triggered the lineage and participated in Ab-Env coevolution. Next-generation sequencing of the Ab repertoire showed an early expansive diversification of the lineage followed by independent maturation of individual limbs, several of them developing notable breadth and potency. Overall, the findings are encouraging from a vaccine standpoint and suggest immunization strategies mimicking the evolution of the entire high-mannose patch and promoting maturation of multiple diverse Ab pathways.


Scientific Reports | 2015

Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding

Linling He; Devin Sok; Parisa Azadnia; Jessica Hsueh; Elise Landais; Melissa Simek; Wayne C. Koff; Pascal Poignard; Dennis R. Burton; Jiang Zhu

B-cell repertoire analysis using next-generation sequencing has become a valuable tool for interrogating the genetic record of humoral response to infection. However, key obstacles such as low throughput, short read length, high error rate, and undetermined bias of multiplex PCR method have hindered broader application of this technology. In this study, we report several technical advances in antibody repertoire sequencing. We first demonstrated the ability to sequence antibody variable domains using the Ion Torrent PGM platform. As a test case, we analyzed the PGT121 class of antibodies from IAVI donor 17, an HIV-1-infected individual. We then obtained “unbiased” antibody repertoires by sequencing the 5′-RACE PCR products of B-cell transcripts from IAVI donor 17 and two HIV-1-uninfected individuals. We also quantified the bias of previously published gene-specific primers by comparing the repertoires generated by 5′-RACE PCR and multiplex PCR. We further developed a single-molecule barcoding strategy to reduce PCR-based amplification noise. Lastly, we evaluated several new PGM technologies in the context of antibody sequencing. We expect that, based upon long-read and high-fidelity next-generation sequencing technologies, the unbiased analysis will provide a more accurate view of the overall antibody repertoire while the barcoding strategy will facilitate high-resolution analysis of individual antibody families.


Journal of Immunology | 2009

New Design of MHC Class II Tetramers to Accommodate Fundamental Principles of Antigen Presentation

Elise Landais; Pablo A. Romagnoli; Adam L. Corper; John Shires; John D. Altman; Ian A. Wilson; K. Christopher Garcia; Luc Teyton

Direct identification and isolation of Ag-specific T cells became possible with the development of MHC tetramers, based on fluorescent avidins displaying biotinylated peptide-MHC complexes. This approach, extensively used for MHC class I-restricted T cells, has met very limited success with class II peptide-MHC complex tetramers (pMHCT-2) for the detection of CD4+-specific T cells. In addition, a very large number of these reagents, although capable of specifically activating T cells after being coated on solid support, is still unable to stain. To try to understand this puzzle and design usable tetramers, we examined each parameter critical for the production of pMHCT-2 using the I-Ad-OVA system as a model. Through this process, the geometry of peptide-MHC display by avidin tetramers was examined, as well as the stability of rMHC molecules. However, we discovered that the most important factor limiting the reactivity of pMHCT-2 was the display of peptides. Indeed, long peptides, as presented by MHC class II molecules, can be bound to I-A/HLA-DQ molecules in more than one register, as suggested by structural studies. This mode of anchorless peptide binding allows the selection of a broader repertoire on single peptides and should favor anti-infectious immune responses. Thus, beyond the technical improvements that we propose, the redesign of pMHCT-2 will give us the tools to evaluate the real size of the CD4 T cell repertoire and help us in the production and testing of new vaccines.


Journal of Clinical Investigation | 2012

Scavenger receptors target glycolipids for natural killer T cell activation

Stefan Freigang; Elise Landais; Victoria Zadorozhny; Lisa Kain; Kenji Yoshida; Yang Liu; Shenglou Deng; Wulf Palinski; Paul B. Savage; Albert Bendelac; Luc Teyton

NKT cells are innate-like T cells with powerful regulatory functions that are a promising target for immunotherapy. The efficacy of glycolipids, such as the prototypic NKT cell antagonist α-galactosylceramide (αGalCer), is currently being evaluated in clinical trials, but little is known about factors that target lipid antigens for CD1d presentation and NKT cell activation in vivo. Lipid uptake via the LDL receptor (LDLR) has been shown for digalactosylceramide; however, whether this pathway contributes to CD1d presentation of other important NKT cell agonists remains unclear. We therefore investigated receptor-mediated uptake pathways for CD1d presentation using a panel of structurally diverse lipid antigens. We found that uptake via scavenger receptors was essential for the CD1d presentation of αGalCer and Sphingomonas glycolipids. Moreover, in vivo NKT cell responses, i.e., cytokine production, proliferation, and NKT cell help for adaptive CD4+ and CD8+ T cells, required the uptake of αGalCer via scavenger receptor A. Importantly, our data indicate that structural characteristics of glycolipids determine their receptor binding and direct individual lipids toward different uptake pathways. These results reveal an important contribution of scavenger receptors in the selection of lipids for CD1d presentation and identify structural motifs that may prove useful for therapeutic NKT cell vaccination.


Nature microbiology | 2017

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

Marit J. van Gils; Tom L. G. M. van den Kerkhof; Gabriel Ozorowski; Christopher A. Cottrell; Devin Sok; Matthias Pauthner; Jesper Pallesen; Natalia de Val; Anila Yasmeen; Steven W. de Taeye; Anna Schorcht; Stephanie Gumbs; Inez Johanna; Karen L. Saye-Francisco; Chi-Hui Liang; Elise Landais; Xiaoyan Nie; Laura K. Pritchard; Max Crispin; Garnett Kelsoe; Ian A. Wilson; Hanneke Schuitemaker; Per Johan Klasse; John P. Moore; Dennis R. Burton; Andrew B. Ward; Rogier W. Sanders

The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutralizing various HIV-1 viral strains is challenging, but understanding how a subset of HIV-infected individuals develops bNAbs may guide immunization strategies. Here, we describe the isolation and characterization of the bNAb ACS202 from an elite neutralizer that recognizes a new, trimer-specific and cleavage-dependent epitope at the gp120–gp41 interface of the envelope glycoprotein (Env), involving the glycan N88 and the gp41 fusion peptide. In addition, an Env trimer, AMC011 SOSIP.v4.2, based on early virus isolates from the same elite neutralizer, was constructed, and its structure by cryo-electron microscopy at 6.2 Å resolution reveals a closed, pre-fusion conformation similar to that of the BG505 SOSIP.664 trimer. The availability of a native-like Env trimer and a bNAb from the same elite neutralizer provides the opportunity to design vaccination strategies aimed at generating similar bNAbs against a key functional site on HIV-1.


Vaccine | 2014

Profiling human antibody responses by integrated single-cell analysis

Adebola O. Ogunniyi; Brittany Anne Thomas; Timothy J. Politano; Navin Varadarajan; Elise Landais; Pascal Poignard; Bruce D. Walker; Douglas S. Kwon; J. Christopher Love

Comprehensive characterization of the antigen-specific B cells induced during infections or following vaccination would facilitate the discovery of novel antibodies and inform how interventions shape protective humoral responses. The analysis of human B cells and their antibodies has been performed using flow cytometry to evaluate memory B cells and expanded plasmablasts, while microtechnologies have also provided a useful tool to examine plasmablasts/plasma cells after vaccination. Here we present an integrated analytical platform, using arrays of subnanoliter wells (nanowells), for constructing detailed profiles for human B cells comprising the immunophenotypes of these cells, the distribution of isotypes of the secreted antibodies, the specificity and relative affinity for defined antigens, and for a subset of cells, the genes encoding the heavy and light chains. The approach combines on-chip image cytometry, microengraving, and single-cell RT-PCR. Using clinical samples from HIV-infected subjects, we demonstrate that the method can identify antigen-specific neutralizing antibodies, is compatible with both plasmablasts/plasma cells and activated memory B cells, and is well-suited for characterizing the limited numbers of B cells isolated from tissue biopsies (e.g., colon biopsies). The technology should facilitate detailed analyses of human humoral responses for evaluating vaccines and their ability to raise protective antibody responses across multiple anatomical compartments.


Immunity | 2017

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage

Elise Landais; Ben Murrell; Bryan Briney; Sasha Murrell; Kimmo Rantalainen; Zachary T. Berndsen; Alejandra Ramos; Lalinda Wickramasinghe; Melissa Laird Smith; Kemal Eren; Natalia de Val; Mengyu Wu; Audrey Cappelletti; Jeffrey C. Umotoy; Yolanda Lie; Terri Wrin; Paul Algate; Po-Ying Chan-Hui; Etienne Karita; Andrew B. Ward; Ian A. Wilson; Dennis R. Burton; Davey M. Smith; Sergei L. Kosakovsky Pond; Pascal Poignard

SUMMARY Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natural infection can help guide the rational design of an HIV vaccine. Here, we described a bnAb lineage targeting the Env V2 apex and the Ab‐Env co‐evolution that led to development of neutralization breadth. The lineage Abs bore an anionic heavy chain complementarity‐determining region 3 (CDRH3) of 25 amino acids, among the shortest known for this class of Abs, and achieved breadth with only 10% nucleotide somatic hypermutation and no insertions or deletions. The data suggested a role for Env glycoform heterogeneity in the activation of the lineage germline B cell. Finally, we showed that localized diversity at key V2 epitope residues drove bnAb maturation toward breadth, mirroring the Env evolution pattern described for another donor who developed V2‐apex targeting bnAbs. Overall, these findings suggest potential strategies for vaccine approaches based on germline‐targeting and serial immunogen design. HIGHLIGHTSIsolation of PCT64, a PGT145‐like, 25‐aa CDRH3 HIV Env V2 apex bnAb lineageEnv glycoform heterogeneity plays a role in the lineage precursor B cell activationLocalized diversity at key V2 epitope residues drove bnAb maturation toward breadthEnv evolution pattern is similar to CAP256, another V2 apex broad neutralizer Understanding the molecular basis of HIV Env‐specific broadly neutralizing antibodies (bnAbs) development is key for vaccine design. Landais et al. find that glycan heterogeneity played a role in the activation of V2 apex PCT64 bnAbs precursor and that viral evolution was similar to CAP256, another donor with V2 apex bnAbs.

Collaboration


Dive into the Elise Landais's collaboration.

Top Co-Authors

Avatar

Pascal Poignard

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Ian A. Wilson

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Ben Murrell

University of California

View shared research outputs
Top Co-Authors

Avatar

Colin Havenar-Daughton

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Shane Crotty

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Alejandra Ramos

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Andrew B. Ward

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Davey M. Smith

University of California

View shared research outputs
Top Co-Authors

Avatar

Dennis R. Burton

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Etienne Karita

International AIDS Vaccine Initiative

View shared research outputs
Researchain Logo
Decentralizing Knowledge